ABSTRACT
Background@#Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy. @*Methods@#This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years. @*Conclusion@#The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.
ABSTRACT
Background@#Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy. @*Methods@#This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years. @*Conclusion@#The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.
ABSTRACT
The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.
Subject(s)
Adult , Female , Humans , Middle Aged , Brain Neoplasms , Brain , Breast Neoplasms , Breast , Drug Therapy , Lung , Mesylates , Microtubules , Neoplasm Metastasis , Phenobarbital , Prognosis , Radiotherapy , ErbB ReceptorsABSTRACT
We report an extremely rare case of papillary thyroid microcarcinoma (PTMC) in the thyroid Epub ahead of print pyramidal lobe (TPL). A 48-year-old woman underwent ultrasound-guided fine-needle aspiration for a small thyroid nodule in the right lobe in local clinic, and it revealed a malignant cytology. On preoperative ultrasonography for tumor staging in our hospital, another small suspiciously malignant hypoechoic nodule was detected in the left TPL. Total thyroidectomy and central nodal dissection were performed. Histopathology confirmed PTMCs in the left TPL and both thyroid lobes. Ultrasonography for TPL should be required for complete evaluation of possible multifocality of thyroid malignancy.
Subject(s)
Female , Humans , Middle Aged , Biopsy, Fine-Needle , Neoplasm Staging , Thyroid Gland , Thyroid Nodule , Thyroidectomy , UltrasonographyABSTRACT
PURPOSE: Hashimoto's thyroiditis (HT) is an important cause of hypothyroidism caused by autoimmune chronic lymphocytic thyroiditis. In order to attain a better understanding for use in treatment of papillary thyroid carcinoma (PTC) coexisting with HT, we conducted an analysis of the clinicopathologic features, as well as the importance of HT as a prognostic factor. METHODS: In this retrospective study, we analyzed 341 patients who were histopathologically diagnosed with PTC following surgery. RESULTS: PTC coexisting with HT was observed in 19.6% (67 patients) of all PTC patients. A statistically significant gender difference was observed in the group with HT (two male vs. 65 female), with a higher positive rate of anti-thyroglobulin antibody and smaller tumor size, compared to the PTC group without HT. When tumor size increased, a lower coexistence rate of HT was observed. No significant differences were observed in multifocality, cervical lymph node (LN) metastasis, coexistence of benign nodule, and extent of LN dissection. However, frequency of extrathyroidal extension was significantly lower and total thyroidectomy rate was higher in the group with HT. TNM stage and AMES stage were similar in both groups; frequency of high MACIS score showed a significant decrease in the group with HT. The recurrence rate and disease- free survival in patients with PTC were not significantly affected by coexistence of HT. CONCLUSION: We found a significant relationship with gender, extrathyroidal extension, and tumor size in PTC coexisting with HT. However, no significant differences in recurrence rate and disease-free survival were observed between groups. Therefore, coexistence in PTC could not be applicable as a prognostic factor of PTC.
Subject(s)
Humans , Male , Disease-Free Survival , Hashimoto Disease , Hypothyroidism , Lymph Nodes , Neoplasm Metastasis , Prognosis , Recurrence , Retrospective Studies , Thyroid Gland , Thyroid Neoplasms , Thyroidectomy , ThyroiditisABSTRACT
PURPOSE: Extrathyroidal extension (ETE) is a risk factor for the recurrence of a papillary thyroid carcinoma (PTC). In the TNM 6(th) classification system, an extrathyroidal invasion of a differentiated thyroid carcinoma has been classified as T3 (minimal invasion), T4a (extended invasion), and T4b (more extensive unresectable invasion) according to tumor invasion. We investigated the clinicopathologic characteristics, recurrence, and disease-free survival (DFS) of minimal ETE (mETE). METHODS: We retrospectively evaluated 332 patients who underwent a thyroidectomy for PTC from January 2005 to December 2006. RESULTS: Of the 332 patients, 103 (31.0%) were found to have a PTC with mETE and 229 (69.0%) patients had a PTC without mETE. In PTC, mETE was related to gender, tumor size, multifocality, Lymph node (LN) metastasis, underlying Hashimoto's thyroiditis, and surgery. But there is no significant difference in age, recurrence, and LN metastasis between the mETE and No mETE groups. Multivariate analysis demonstrated that LN metastasis (odds ratio=2.273; 95% confidence interval 1.280~4.037) was recognized as an independent factor for mETE (P=0.005). Disease-free survival was not significantly different between patients with and without mETE (P=0.153). We analyzed the effect of LN metastasis in groups with and without mETE. Based on the presence or absence of LN metastasis, disease-free survival (DFS) rates between each group showed no significant differences. CONCLUSION: Minimal ETE had no impact on DFS in patients with PTC. Therefore, an appropriate surgical approach and postoperative follow-up are required for tumors with mETE.
Subject(s)
Humans , Classification , Disease-Free Survival , Follow-Up Studies , Lymph Nodes , Multivariate Analysis , Neoplasm Metastasis , Recurrence , Retrospective Studies , Risk Factors , Thyroid Gland , Thyroid Neoplasms , Thyroidectomy , ThyroiditisABSTRACT
PURPOSE: Laparoscopic cholecystectomy (LC) has been the treatment of choice for acute and chronic disease of the gallbladder. We have performed 621 cases of LC from January 02 2001 to April 30 2008. This study aims to clinically analyze 621 cases of LC that were performed by a single surgeon over a 7 year period and to evaluate the effectiveness and safety of laparoscopic treatment for gallbladder disease. METHODS: From January 02 2001 to April 30 2008, 621 patients underwent LC at the Department of Surgery by a single surgeon. We retrospectively analyzed the patients' ages, gender distribution and chief complaints, the operation times, the duration of hospitalization, the conversion rate to open cholecystectomy and the causes, the diagnostic methods and the postoperative complications through a review of the patients' charts. RESULTS: The mean age was 46 years and the ratio of males to females was 1:1.4. The most common chief complaint was right upper quadrant pain (52.97%). The mean operative time was 67.37 minutes and the duration of hospitalization was 5.12 days and the duration of postoperative hospitalization was 3.86 days. The conversion rate was 3.29% and the most common cause of conversion was anatomic uncertainty due to inflammatory adhesion. Abdominal sonography was the most common diagnostic method and this was performed in 73.27% of the patients. The postoperative complication rate was 1.93%. CONCLUSION: LC has become the gold standard for the treatment of benign gallbladder diseases. We think that LC is effective and safe, and even at a secondary care hospital, if the surgeon has accumulated operative experience and improved operative skill.